Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.
Veruschka AlbertGerhard PiendlDali YousseffHedwig LammertMichael HummelOlaf OrtmannWolfgang JaglaAndreas GaumannAnja K WegeGero BrockhoffPublished in: Archives of gynecology and obstetrics (2022)
A combined targeting of PKC and a subtype specific driver molecule might complement specified breast cancer treatment.